nasal vaccine - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Will Iran strikes on Dubai delay Wynn Al Marjan Island and what does it mean for WYNN investors?

Blackstone (NYSE: BX) to acquire majority stake in Advanced Cooling Technologies as AI data centre heat surge reshapes thermal management market

Representative image of enterprise data center infrastructure and networking hardware illustrating Hewlett Packard Enterprise’s fiscal 2026 growth momentum, as strong networking revenue following the Juniper Networks acquisition drives higher earnings, improved free cash flow, and renewed investor focus on HPE’s evolving AI and infrastructure strategy.

Hewlett Packard Enterprise (NYSE: HPE) raises FY2026 guidance after Q1 beat fuelled by Juniper integration and AI networking demand

Representative image: Oracle (NYSE: ORCL) stock jumps 13% on record cloud earnings and multicloud momentum

Oracle (NYSE: ORCL) rallies 10% after earnings as $553bn RPO signals AI infrastructure dominance

CyanVac’s nasal COVID-19 vaccine

Read More

5 minute read

Pharma Industry News

CyanVac’s nasal COVID-19 vaccine shows strong immune response in U.S. phase 1 clinical trial

CyanVac’s nasal COVID-19 vaccine shows strong mucosal immune response in U.S. phase 1 trial. Larger studies underway to assess full efficacy.

byPallavi Madhiraju

July 5, 2025

web analytics